Global Biopharmaceutical Contract Manufacturing Markets, 2022-2035: Focus on Niche Therapeutic Areas, Integration/Adoption of Innovative Technologies, Increase in Financial Inflow and Budgets
2022-11-03
基因疗法抗体生物类似药细胞疗法疫苗
DUBLIN, Nov. 3, 2022 /PRNewswire/ -- The "Biopharmaceutical Contract Manufacturing Market by Type of Service Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022 - 2035" report has been added to
ResearchAndMarkets.com's offering.
The "Biopharmaceutical Contract Manufacturing Market" report features an extensive study of the current market landscape and the likely future potential associated with the biopharmaceutical contract manufacturing market, over the next decade.
Over the last few decades, the development landscape of small molecule drugs has been significantly impacted by various biotechnology breakthroughs.
Further, with the advent of novel technologies, biologics have made a significant impact in the pharmaceutical domain, delivering ground-breaking treatment for a myriad of disease indications, including immunological, oncological and rare disorders. In this context, it is worth highlighting those 14 biopharmaceutical products (including cell therapies, gene therapies, monoclonal antibodies and recombinant proteins) were approved in the US alone, in 2021.
Further, promising results from ongoing clinical research initiatives have encouraged various government and private firms to make significant investments in this domain. For instance, in 2021, a sum of over USD 70 billion was invested in the cell and gene therapy domain. However, biologics manufacturing is fraught with various challenges.
Some of the key concerns of contemporary innovators include rate of attrition of pipeline drugs / therapies, prolonged development timelines, current facility limitations, regulatory and compliance-related issues, and inconsistencies related to quality attributes of the final product. Therefore, therapy developers are actively exploring avenues that enable them to overcome the existing challenges. Amongst other alternatives, outsourcing has emerged as a lucrative option for biologic drug developers.
Currently, a significant number of players engaged in the biopharmaceutical domain prefer to outsource various operations to contract service providers (such as biologics manufacturing). In fact, currently over 275 companies claim to be biopharma CDMO / biopharma CMO, in compliance with the regulatory standards. It is also worth highlighting that biopharmaceutical contract manufacturers are actively trying to consolidate their presence in this field by entering into strategic alliances in order to meet the indubitably rising demand for biologics.
For this purpose, substantial expansions, and mergers and acquisitions have been reported in this market, as service providers strive to become one-stop-shops, to cater to the diverse needs of their clientele. With outsourcing being increasingly accepted as a viable and beneficial business model within this field, we anticipate the biopharmaceutical contract manufacturing market (biopharma CDMO / biopharma CMO) to grow at a commendable pace in the coming years.
Scope of the Report
One of the key objectives of the report was to estimate the existing market size and estimate the future size of biopharmaceutical contract manufacturing market. We have provided informed estimates on the evolution of the market, over the period 2022-2035.
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.
Our year-wise projections of the current and future opportunity have further been segmented on the basis of
Type of service(s) offered (API, FDF)
Type of biologic manufactured (antibodies, cell therapies, vaccines and other biologics),
Type of expression system used (mammalian, microbial and others)
Scale of operation (preclinical / clinical and commercial)
Company size (small, mid-sized, and large and very large)
Key geographical regions (North America, Europe, Asia-Pacific, Latin America and MENA).
Key Questions Answered
Who are the key players engaged in offering contract manufacturing services for biopharmaceuticals?
What are the different partnerships and expansion initiatives undertaken by biopharmaceutical contract manufacturers in the recent past?
Which regions represent the current key contract manufacturing hubs for biopharmaceuticals?
What is the current, installed capacity for contract manufacturing of biopharmaceuticals?
What is the current, global demand for biologics? How is the demand for such candidates likely to evolve in the foreseen future?
What percentage of the biopharmaceuticals manufacturing operations are presently outsourced?
What factors should be taken into consideration while deciding whether the manufacturing operations for biopharmaceuticals should be kept in-house or outsourced?
How is the current and future opportunity likely to be distributed across key market segments?
Future of the Biopharmaceutical CMOs Market
Outsourcing Activities to Witness Significant Growth in the Coming Years
Shift from One-time Contracts to Strategic Partnerships
Integration / Adoption of Innovative Technologies
Focus on Niche Therapeutic Areas
Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
Capability and Expertise Expansions by CMOs to become One-Stop-Shops
Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
Increase in Financial Inflow and Outsourcing Budgets
Challenges Faced by both Sponsors and Service Providers
Concluding Remarks
Leading Biopharmaceutical CMOs
Leading Biopharmaceutical CMOs in North America
Catalent (Catalent Pharma Solutions)
Cytiva (GE Healthcare)
Patheon (acquired by Thermo Fisher Scientific)
Leading Biopharmaceutical CMOs in Europe
Boehringer Ingelheim (BioXcellence)
Novasep
Olon
Leading Biopharmaceutical CMOs in China
Leading Biopharmaceutical CMOs in India
Leading Biopharmaceutical CMOs in Japan
Takara Bio
Biopharmaceutical Contract Manufacturing in South Korea
Celltrion
Samsung BioLogics
Leading Biopharmaceutical CMOs in Australia
Key Topics Covered:
1. Preface
3. Introduction
4. Market Landscape
6. Biopharmaceutical Contract Manufacturing in North America
7. Biopharmaceutical Contract Manufacturing in Europe
8. Biopharmaceutical Contract Manufacturing in Asia-Pacific and the Rest of the World
9. Niche Biopharmaceutical Sectors
10. Case Study: Outsourcing of Biosimilars
11. Case Study: Comparison of Small and Large Molecules Drugs / Therapies
12. Case Study: In-House Manufacturing
13. Make Versus Buy Decision Making Framework
14. Big Pharma Initiatives
15. Partnerships and Collaborations
16. Mergers and Acquisitions
17. Recent Expansions
18. Recent Developments
20. Demand Analysis
21. Total Cost of Ownership for Biopharmaceutical Contract Manufacturing Organizations
22. Market Forecast and Opportunity Analysis
23. Case Study: Virtual Pharmaceutical Companies
24. SWOT Analysis
25. Future of the Biopharmaceutical CMO Market
26. Survey Analysis
27. Conclusion
28. Interview Transcripts
For more information about this report visit https://www.researchandmarkets.com/r/8ibnim
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-药物
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。